Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06437353
Other study ID # 2024 No. 047
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 25, 2024
Est. completion date October 30, 2027

Study information

Verified date May 2024
Source Anhui Provincial Cancer Hospital
Contact Bai-Rong Xia, Doctor
Phone 18604516165
Email xiabairong9999@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly diagnosed high-risk ovarian cancer


Description:

Patients will have tests and exams to see if they are eligible for the clinical trial. First-line chemotherapy regimen: Paclitaxel/Carboplatin(repeat every 3 weeks, total of 6 cycles): - Paclitaxel: 175 mg/m², intravenous infusion, on day 1. - Carboplatin: AUC 5, intravenous infusion, on day 1. - For patients aged ≥70 years or those with comorbidities, the paclitaxel dose can be adjusted to 135 mg/m². Surufatinib(repeat every 3 weeks, total of 5 cycles): - Surufatinib is not used during the first postoperative cycle. - Starting from the second postoperative cycle, surufatinib is administered at a dose of 250 mg once daily, taken continuously. Maintenance Therapy Regimen: HRD-positive Patients: - Surufatinib: 250 mg once daily, taken continuously. - Olaparib: 300 mg twice daily, with doses taken 12 hours apart. Olaparib can be used for a maximum of 2 years. HRD-negative or HRD Status Unknown Patients: - Surufatinib: 250 mg once daily, taken continuously. Treatment continues until the patient experiences disease progression or meets other criteria for discontinuation of the study treatment as specified in the protocol.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 30, 2027
Est. primary completion date October 30, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age: 18-75 years old (=18, =75) 2. Patients with newly diagnosed FIGO stage III or IV high-grade serous ovarian cancer, high-grade endometrioid carcinoma, primary peritoneal cancer, and/or fallopian tube cancer with high-risk factors for recurrence. High-risk recurrence is defined as follows: - FIGO stage III with non-R0 resection; - FIGO stage IV; - Presence of ascites at initial diagnosis. 3. Patients who have undergone primary debulking surgery (PDS) for ovarian cancer. 4. ECOG performance status score: 0-2. 5. Postoperative administration time =12 weeks. 6. Expected survival of at least 3 months. 7. Major organ function within 7 days prior to treatment meets the following criteria: - Hemoglobin (HB) =90 g/L; - Absolute neutrophil count (ANC) =1.5×10?/L; - Platelets (PLT) =100×10?/L. 8. Biochemical parameters must meet the following standards: - Total bilirubin (TBIL) =1.5 times the upper limit of normal (ULN); - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5×ULN, or =5×ULN if liver metastases are present; - Serum creatinine (Cr) =1.5×ULN or creatinine clearance (CCr) =60 ml/min. 9. Women of childbearing potential must use effective contraception. 10. Subjects must voluntarily join the study and sign the informed consent form (ICF). 11. Subjects are expected to have good compliance and the ability to follow up on efficacy and adverse reactions as required by the protocol. Exclusion Criteria: 1. Previous treatment with anti-angiogenic drugs such as apatinib, sorafenib, anlotinib, bevacizumab, or other anti-angiogenic therapies. 2. Pregnant or breastfeeding women. 3. Patients who have previously participated in other clinical trials that have not yet concluded. 4. Patients with evidence or history of significant bleeding tendencies or events within 3 months before enrollment (bleeding >30 mL, accompanied by hematemesis, melena, or hematochezia), hemoptysis (=5 mL of fresh blood within 4 weeks), or thromboembolic events (including stroke and/or transient ischemic attack) within 12 months. 5. Patients with uncontrolled hypertension (systolic blood pressure =150 mmHg or diastolic blood pressure =100 mmHg). 6. Patients with grade I or higher myocardial ischemia or infarction, arrhythmias (including QTc =480 ms), or = grade 2 congestive heart failure (New York Heart Association (NYHA) classification). 7. Patients with active or uncontrolled severe infections (=CTC AE grade 2). 8. Patients with renal failure requiring hemodialysis or peritoneal dialysis. 9. Patients with a history of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases, or those with a history of organ transplantation. 10. Patients with persistent proteinuria (=++) on two consecutive urine tests, and confirmed 24-hour urine protein >1.0 g. 11. Patients with psychiatric disorders, including epilepsy, dementia, severe depression, mania, etc. 12. Patients with any signs or history of bleeding disorders, regardless of severity; patients who experienced any bleeding or hemorrhagic event =CTCAE grade 3 within 4 weeks before enrollment; patients with unhealed wounds, ulcers, or fractures. 13. Patients who had arterial or venous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism, within the past 6 months. 14. Patients with symptomatic brain metastases or those whose symptoms have been controlled for less than 2 months. 15. Patients with a history of substance abuse that cannot be relinquished or those with psychiatric disorders. 16. Patients with difficulty swallowing or known absorption disorders affecting drug intake. 17. Patients allergic to treatment drugs sorafenib or paclitaxel/carboplatin. 18. Any other condition that the researcher deems unsuitable for enrollment.

Study Design


Intervention

Drug:
Paclitaxel
First-line chemotherapy regimen: Paclitaxel: 175 mg/m², intravenous infusion, on day 1. Carboplatin: AUC 5, intravenous infusion, on day 1. Surufatinib:250 mg once daily, taken continuously. Maintenance Therapy Regimen: Surufatinib: 250 mg once daily, taken continuously. Olaparib: 300 mg twice daily.

Locations

Country Name City State
China Anhui Cancer Hospital Hefei Anhui

Sponsors (2)

Lead Sponsor Collaborator
Anhui Provincial Cancer Hospital Hutchison Medipharma Limited

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival Progression-free survival on first-line and maintenance therapy with Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib 12-month
Secondary Overall Response Rate (ORR ORR is defined as the proportion of participants achieving Complete Response (CR) or Partial Response (PR) as assessed by the investigator per RECIST (v.1.1). Per RECIST 1.1, CR is defined as the disappearance of all target lesions; PR is defined as at least a 30% decrease in the sum of diameters (SoD) of target lesions 3-month
Secondary Disease control rate the percentage of patients with complete response, partial response, and stable disease for more than 4 weeks in which response can be evaluated 3-month
Secondary Overall survival the date of enrollment to the date of death from any cause 3-years
Secondary Adverse event Adverse medical events in clinical trial subjects treated with Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib 3-month
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2